Literature DB >> 19135199

Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study.

Renate Schnabel1, Josée Dupuis, Martin G Larson, Kathryn L Lunetta, Sander J Robins, Yanyan Zhu, Jian Rong, Xiaoyan Yin, Heide A Stirnadel, Jeanne J Nelson, Peter W F Wilson, John F Keaney, Ramachandran S Vasan, Emelia J Benjamin.   

Abstract

OBJECTIVE: To conduct an investigation of clinical and genetic correlates of lipoprotein-associated phospholipase (Lp-PLA(2)) activity and mass in a large community-based cohort. Higher circulating Lp-PLA(2) predicts cardiovascular disease risk, but sources of inter-individual variability are incompletely understood.
METHODS: We conducted stepwise regression of clinical correlates of Lp-PLA(2) in four Framingham Heart Study cohorts (n=8185; mean age 50+/-14 years, 53.8% women, 9.8% ethnic/racial minority cohort). We also conducted heritability and linkage analyses in Offspring and Generation 3 cohorts (n=6945). In Offspring cohort participants we performed association analyses (n=1535 unrelated) with 1943 common tagging SNPs in 233 inflammatory candidate genes.
RESULTS: Sixteen clinical variables explained 57% of the variability in Lp-PLA(2) activity; covariates associated with Lp-PLA(2) mass were similar but only explained 27% of the variability. Multivariable-adjusted heritability estimates for Lp-PLA(2) activity and mass were 41% and 25%, respectively. A linkage peak was observed for Lp-PLA(2) activity (chromosome 6, LOD score 2.4). None of the SNPs achieved experiment-wide statistical significance, though 12 had q values <0.50, and hence we expect at least 50% of these associations to be true positives. The strongest multivariable-association with Lp-PLA(2) activity was found for MEF2A (rs2033547; nominal p=3.20 x 10(-4)); SNP rs1051931 in PLA2G7 was nominally associated (p=1.26 x 10(-3)). The most significant association to Lp-PLA(2) mass was in VEGFC (rs10520358, p=9.14 x 10(-4)).
CONCLUSIONS: Cardiovascular risk factors and genetic variation contribute to variability in Lp-PLA(2) activity and mass. Our genetic association analyses need replication, which will be facilitated by web posting of our genetic association results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19135199      PMCID: PMC2893025          DOI: 10.1016/j.atherosclerosis.2008.10.030

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  28 in total

1.  Mapping quantitative trait loci in oligogenic models.

Authors:  H K Tang; D Siegmund
Journal:  Biostatistics       Date:  2001-06       Impact factor: 5.899

2.  Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes.

Authors:  Hoon-Suk Cha; Eun-Kyung Bae; Jay-Hyun Koh; Ji-Young Chai; Chan Hong Jeon; Kwang-Sung Ahn; Jinseok Kim; Eun-Mi Koh
Journal:  J Rheumatol       Date:  2007-01       Impact factor: 4.666

3.  The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma.

Authors:  S Kruse; X Q Mao; A Heinzmann; S Blattmann; M H Roberts; S Braun; P S Gao; J Forster; J Kuehr; J M Hopkin; T Shirakawa; K A Deichmann
Journal:  Am J Hum Genet       Date:  2000-03-24       Impact factor: 11.025

4.  Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins.

Authors:  R Guerra; B Zhao; V Mooser; D Stafforini; J M Johnston; J C Cohen
Journal:  J Lipid Res       Date:  1997-11       Impact factor: 5.922

Review 5.  Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.

Authors:  Carolina A Garza; Victor M Montori; Joseph P McConnell; Virend K Somers; Iftikhar J Kullo; Francisco Lopez-Jimenez
Journal:  Mayo Clin Proc       Date:  2007-02       Impact factor: 7.616

6.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

Authors:  C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

7.  Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.

Authors:  Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Peter J Koudstaal; Theo Stijnen; Monique M B Breteler; Jacqueline C M Witteman
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

8.  The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort.

Authors:  Margaretha Persson; Jan-Ake Nilsson; Jeanenne J Nelson; Bo Hedblad; Göran Berglund
Journal:  Atherosclerosis       Date:  2006-03-13       Impact factor: 5.162

9.  Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.

Authors:  Michelle O'Donoghue; David A Morrow; Marc S Sabatine; Sabina A Murphy; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
Journal:  Circulation       Date:  2006-03-14       Impact factor: 29.690

10.  Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population.

Authors:  Shao-Yan Zhang; Hiroshi Shibata; Kenji Karino; Bin-You Wang; Shotai Kobayashi; Junichi Masuda; Toru Nabika
Journal:  Hypertens Res       Date:  2007-05       Impact factor: 3.872

View more
  14 in total

1.  Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.

Authors:  Harald Grallert; Josée Dupuis; Joshua C Bis; Abbas Dehghan; Maja Barbalic; Jens Baumert; Chen Lu; Nicholas L Smith; André G Uitterlinden; Robert Roberts; Natalie Khuseyinova; Renate B Schnabel; Kenneth M Rice; Fernando Rivadeneira; Ron C Hoogeveen; João Daniel Fontes; Christa Meisinger; John F Keaney; Rozenn Lemaitre; Yurii S Aulchenko; Ramachandran S Vasan; Stephen Ellis; Stanley L Hazen; Cornelia M van Duijn; Jeanenne J Nelson; Winfried März; Heribert Schunkert; Ruth M McPherson; Heide A Stirnadel-Farrant; Bruce M Psaty; Christian Gieger; David Siscovick; Albert Hofman; Thomas Illig; Mary Cushman; Jennifer F Yamamoto; Jerome I Rotter; Martin G Larson; Alexandre F R Stewart; Eric Boerwinkle; Jacqueline C M Witteman; Russell P Tracy; Wolfgang Koenig; Emelia J Benjamin; Christie M Ballantyne
Journal:  Eur Heart J       Date:  2011-10-14       Impact factor: 29.983

2.  Short-term hyperglycaemia causes non-reversible changes in arterial gene expression in a fully 'switchable' in vivo mouse model of diabetes.

Authors:  S Zervou; Y-F Wang; A Laiho; A Gyenesei; L Kytömäki; R Hermann; S Abouna; D Epstein; S Pelengaris; M Khan
Journal:  Diabetologia       Date:  2010-09-16       Impact factor: 10.122

3.  Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.

Authors:  Sunil Suchindran; David Rivedal; John R Guyton; Tom Milledge; Xiaoyi Gao; Ashlee Benjamin; Jennifer Rowell; Geoffrey S Ginsburg; Jeanette J McCarthy
Journal:  PLoS Genet       Date:  2010-04-29       Impact factor: 5.917

4.  Mapping quantitative traits in unselected families: algorithms and examples.

Authors:  Josée Dupuis; Jianxin Shi; Alisa K Manning; Emelia J Benjamin; James B Meigs; L Adrienne Cupples; David Siegmund
Journal:  Genet Epidemiol       Date:  2009-11       Impact factor: 2.135

5.  Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population.

Authors:  Guo-Hua Zheng; Shang-Quan Xiong; Hai-Ying Chen; Li-Juan Mei; Ting Wang
Journal:  Mol Biol Rep       Date:  2014-07-18       Impact factor: 2.316

Review 6.  Atherosclerosis and transit of HDL through the lymphatic vasculature.

Authors:  Catherine Martel; Gwendalyn J Randolph
Journal:  Curr Atheroscler Rep       Date:  2013-09       Impact factor: 5.113

7.  PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.

Authors:  Juan P Casas; Ewa Ninio; Andrie Panayiotou; Jutta Palmen; Jackie A Cooper; Sally L Ricketts; Reecha Sofat; Andrew N Nicolaides; James P Corsetti; F Gerry R Fowkes; Ioanna Tzoulaki; Meena Kumari; Eric J Brunner; Mika Kivimaki; Michael G Marmot; Michael M Hoffmann; Karl Winkler; Winfred März; Shu Ye; Heide A Stirnadel; S Matthijs Boekholdt; Kay-Tee Khaw; Steve E Humphries; Manjinder S Sandhu; Aroon D Hingorani; Philippa J Talmud
Journal:  Circulation       Date:  2010-05-17       Impact factor: 29.690

8.  Racial variation in lipoprotein-associated phospholipase A₂ in older adults.

Authors:  Keane K Lee; Stephen P Fortmann; Ann Varady; Joan M Fair; Alan S Go; Thomas Quertermous; Mark A Hlatky; Carlos Iribarren
Journal:  BMC Cardiovasc Disord       Date:  2011-06-29       Impact factor: 2.298

Review 9.  Functional Consequences of Mutations and Polymorphisms in the Coding Region of the PAF Acetylhydrolase (PAF-AH) Gene.

Authors:  Diana M Stafforini
Journal:  Pharmaceuticals (Basel)       Date:  2009-11-20

10.  Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.

Authors:  Julie E Davidson; Andrew Lockhart; Leslie Amos; Heide A Stirnadel-Farrant; Vincent Mooser; Marc Sollberger; Axel Regeniter; Andreas U Monsch; Michael C Irizarry
Journal:  Alzheimers Res Ther       Date:  2012-12-07       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.